AdChem

COSMETICS & PERSONAL CARE

Shin-Etsu

Tokyo, Japan · Producing pharmaceutical excipients since 1962

The cellulose ether standard for oral solid dose.

Almost every oral solid dosage form built in the last forty years has a Shin-Etsu decision somewhere in it: the hypromellose in the film coat, the matrix polymer controlling release, the disintegrant preventing capping, or the enteric polymer deciding where in the gastrointestinal tract the drug is released.

Shin-Etsu Chemical began producing pharmaceutical excipients in 1962 and has developed the substitution chemistry of cellulose ethers further than any other manufacturer. The result is a portfolio where a formulator can move between coating, matrix, disintegration, enteric protection and bioavailability enhancement without leaving one polymer family.

Over 400 mineral salts and more than 7,000 specifications. The specification count is the more meaningful number: it is the measure of how far a grade can be tailored.

ABOUT THIS PRINCIPAL

Sixty years of substitution chemistry.

Shin-Etsu's excipient business is built on control of a single chemistry taken to an unusual level of precision. Hypromellose is not one material: methoxy and hydroxypropoxy substitution levels, viscosity grade, and particle size distribution together determine whether a polymer coats, gels, disintegrates, or protects. Shin-Etsu segments its grades along all of those axes and specifies them tightly enough that a formulation developed at laboratory scale behaves the same way in production.

Regulated grades are manufactured at Naoetsu in Japan, covering METOLOSE, METOLOSE SR, PHARMACOAT, L-HPC, HPMCP and Shin-Etsu AQOAT, and at Wiesbaden in Germany, covering the TYLOPUR and TYLOPUR SR ranges. Both operate under GMP.

The enteric and bioavailability portfolio is where the science is most differentiated. HPMCP has been in use as an enteric coating since 1971. Shin-Etsu AQOAT, a hypromellose acetate succinate, was approved as a pharmaceutical excipient in Japan in 1987, listed in USP/NF in 2005, in JP in 2012, and in EP in 2024. It functions both as an enteric coating and as a solid dispersion carrier for poorly soluble drugs.

AQOAT is the rare excipient that solves two different problems with the same polymer: delayed release, and the amorphous stabilisation of a poorly soluble molecule.

ADCHEM distributes the Shin-Etsu pharmaceutical excipient range with formulation and troubleshooting support from our own laboratories, covering grade selection, coating trials, and matrix release profiling.

FEATURED TECHNOLOGY

Most Shin-Etsu projects fall into one of the following four technical problems.

Coating

Film coating and moisture protection

PHARMACOAT low viscosity hypromellose grades give reproducible film formation, adhesion, and moisture barrier without the mechanical brittleness of higher viscosity polymers.

Release Control

Hydrophilic matrix systems

METOLOSE SR carries tighter specifications than standard grades because matrix release depends on hydration rate and gel strength. It is designed exclusively for the hydrophilic matrix system, the simplest sustained release architecture available.

Enteric Protection

pH-targeted delayed release

HPMCP dissolves in the pH 5 to 5.5 region, tunable by phthalyl content across the HP-50 and HP-55 grades. Shin-Etsu AQOAT extends the range across nine grades with dissolution thresholds from approximately pH 5.5 to 6.5.

Bio Availability

Amorphous solid dispersion

AQOAT is widely used as a carrier for solid dispersions to enhance the solubility of poorly soluble drugs, processed by spray drying or hot melt extrusion. It is a bioavailability tool, not only a coating.

Portfolio

The Shin-Etsu excipient portfolio.

Grade selection is driven by dosage form, release target, and process. The ranges below cover the majority of oral solid dose requirements.

PHARMACOAT

What it is

Hypromellose, low viscosity coating grades, USP

Primary Use

Aqueous and organic film coating, moisture protection, seal coating

What it is

Hypromellose and methylcellulose across a wide viscosity range, USP / EP / JP

Primary Use

Binder, film former, thickener, and viscosity modifier across solid and liquid dosage forms

What it is

Hypromellose grades with tightened substitution and particle specifications for matrix release

Primary Use

Sustained release hydrophilic matrix tablets, by direct compression or wet granulation

What it is

Low-substituted hydroxypropyl cellulose; swells in water without dissolving

Primary Use

Disintegrant and dry binder; capping prevention, direct compression, wet granulation

What it is

Hypromellose phthalate with lower phthalyl content, dissolving at the lower end of the enteric range

Primary Use

Enteric coating where earlier release in the small intestine is required

What it is

Hypromellose phthalate, the more widely used enteric grade

Primary Use

Gastro-resistant coating, protection of acid-labile drugs and of gastric mucosa

What it is

Hypromellose acetate succinate, low grade; dissolution from approximately pH 5.5

Primary Use

Enteric coating and solid dispersion carrier for earlier release profiles

What it is

Hypromellose acetate succinate, medium grade; dissolution from approximately pH 6.0

Primary Use

Enteric coating and amorphous solid dispersion, the most widely used AQOAT grade

What it is

Hypromellose acetate succinate, high grade; dissolution from approximately pH 6.5

Primary Use

Distal delayed release and solid dispersion where later release is targeted

What it is

Fine, medium and granular particle size variants of each AQOAT substitution grade

Primary Use

Fine for fully neutralised aqueous coating and spray drying, granular for organic solution and hot melt extrusion

What it is

Co-processed excipient system for orally disintegrating tablets

Primary Use

ODT formats requiring rapid disintegration with acceptable tablet hardness

What it is

Cellulose ether ranges manufactured at Wiesbaden, Germany

Primary Use

Coating, binding and sustained release, with European manufacture where that is a supply requirement

APPLICATION AREAS

Where Shin-Etsu excipients perform.

Immediate release film coating

PHARMACOAT grades for cosmetic, seal and moisture-barrier coats with predictable spray parameters and low tack.

PHARMACOAT

METOLOSE

Sustained and controlled release

METOLOSE SR hydrophilic matrix systems, the most robust route to a controlled release profile that survives scale-up.

METOLOSE SR

Enteric and delayed release

HPMCP and AQOAT give a tunable dissolution threshold across the physiologically relevant pH range, in aqueous or organic systems.

HPMCP HP-55

AQOAT AS-M

Bioavailability enhancement

AQOAT as an amorphous solid dispersion carrier for BCS class II and IV molecules, via spray drying or hot melt extrusion.

AQOAT

SPRAY DRYING

HME

Disintegration and compression

L-HPC as a multifunctional problem solver for capping, hardness, and disintegration time in direct compression formats.

L-HPC

Orally disintegrating tablets

SmartEx for ODT formats where disintegration speed and tablet robustness are normally in direct conflict.

SMARTEX

DOCUMENTATION TO BE HELD

Regulatory documentation that supports the filing, not just the purchase order.

Shin-Etsu excipients are supplied with the documentation set required for regulatory submission and for supplier qualification: compendial compliance, GMP evidence, impurity and safety declarations, and reference to filed Drug Master Files where applicable. Shin-Etsu also publishes application guides and troubleshooting resources covering tablet defects and enteric coating problems, which shorten development cycles materially.

Product & Quality
  • Product specification sheet
  • Certificate of Analysis (CoA), batch specific
  • Safety Data Sheet (SDS / MSDS)
  • Compendial compliance statement against USP/NF, Ph. Eur., JP or BP as applicable
  • Analytical methods and method validation summary
  • Physical characterisation data: particle size distribution, bulk and tapped density, loss on drying
  • Stability data with retest period or shelf life justification
  • Drug Master File number with Letter of Access
  • Certificate of Suitability (CEP / COS) where filed
  • Written Confirmation for API import into the European Union
  • Manufacturing licence and site registration details
  • Open part documentation for inclusion in the applicant’s submission
  • Regulatory support commitment for market registration and variations
  • GMP certificate for the manufacturing site
  • Excipient GMP statement aligned to IPEC-PQG or EXCiPACT, for excipient grades
  • ISO 9001 certificate
  • Quality Agreement
  • Change control and prior notification commitment
  • Most recent regulatory inspection outcome summary
  • Completed supplier questionnaire or audit report
  • Elemental impurities risk assessment (ICH Q3D)
  • Residual solvents data (ICH Q3C)
  • Genotoxic and mutagenic impurity assessment (ICH M7)
  • Nitrosamine risk evaluation
  • Related substances and impurity profile with named and characterised impurities
  • Microbiological limits and bioburden data
  • Bacterial endotoxin data where the grade or route requires it
  • Manufacturing process flow chart and route of synthesis summary
  • Starting material identity and origin statement
  • TSE / BSE-free declaration
  • GMO-free statement
  • Allergen statement
  • Residual antibiotic and cross-contamination control statement
  • Latex-free and melamine-free statements
  • Country of origin declaration
  • Halal and Kosher certificates where required by the market
  • Packaging and container closure specification

WORKING WITH ADCHEM

What ADCHEM adds to the Shin-Etsu relationship.

DEVELOPMENT SUPPORT

Grade selection against the release target

Hypromellose grade selection is where most oral solid dose projects lose time. We work from the target dissolution profile backwards to viscosity grade and substitution type.

LABORATORY TRIALS

Coating and matrix trials

Our formulation laboratories run coating and matrix trials on the selected grade so the transfer into your production equipment starts from validated parameters.

SUBMISSION-READY

Filing documentation assembly

Compendial statements, DMF references, impurity declarations and GMP evidence compiled into the format your regulatory affairs team needs for submission.

AUTO-ATTACHED VIA COSMO

Full documentation with every sample

Specification, SDS, CoA, compendial statement and applicable declarations dispatched with the sample as standard, via COSMO, our digital platform.

Quick facts
HQ
Tokyo, Japan
Founded
1962
Manufacturing
Naoetsu, Japan and Wiesbaden, Germany (SE Tylose)
SEGMENT
Cellulose ether excipients for oral solid and oral liquid dosage forms
Compendial Status
USP/NF, EP and JP monograph compliance across the principal ranges
Quality System
GMP manufacture, subject to FDA inspection
Application Support
Published application guides, tablet troubleshooting and enteric coating troubleshooting resources

One polymer family, from the coat to the release profile.

Three ways to start: a sample, a technical data sheet, or a conversation with a specialist who can discuss substitution type and dissolution threshold before discussing quantities.

Request a Sample

Any product in the portfolio

Request Technical Data

Full technical library

Talk to Our Specialist

Someone who knows the chemistry first

Other principals in this segment
Pharmaceuticals
Dr. Paul Lohmann
Fuji Chemicals
Gangwal
Nippon Soda
Beneo
Kornnac Capsules
Seppic
Vanderbilt Minerals
Scroll to Top